MONROVIA, CA, October 08, 2009
/24-7PressRelease/ -- GTCbio is proud to present its 7th Annual Vaccines: "All Things Considered" conference to be held this year in Washington, D.C. on Nov 9-10, 2009. This conference promises to be the one-stop destination to gain updates and exposure on all aspects of vaccine research, development, regulations, and policy.
The research and discovery of vaccines to fight globally prevalent diseases has been a major focus of the pharmaceutical industry's biggest players for decades. The pharmaceutical world has been rocked recently by the pending expiration of patents on several major block-buster drugs. How does this affect funding for vaccine research and development? What will be the path forward? How will the generic drug industry affect the vaccines market? These are just a few of the questions the Vaccines conference will address and answer.
Recent advancements in the discovery of novel vaccines that target not only traditional infectious diseases (such as Malaria, Influenza, AIDS, Meningitis, etc), but non-infectious diseases such as cancer, allergies, and even smoking, prove to be both innovative and promising for the industry. The Vaccines conference is the perfect forum to network with colleagues and gain valuable information on these exciting next generation vaccines.
In the spirit of truly considering all things, GTCbio's Vaccines conference will also bring together leading government officials, with representatives from the DHHS and the FDA, to provide a first-hand perspective into current US vaccines policy and regulation. Updates on the pandemic and bio-defense policy as well as the National Vaccine Plan will be addressed and discussed.
Gaining a proficient understanding of and accounting for the aforementioned factors in vital before moving forward with Vaccine discovery and development. Don't miss an opportunity to take all things into consideration and register for GTCbio's 7th Annual Vaccines: "All Things Considered" conference.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com# # #
- adjuvants, avian, conferences, cutaneous, delivery, drug, flu, gtcbio, immunization, influenza, maternal, meningococcus, methods, platforms, rotavirus, toxicology, tuberculosis, vaccination, vaccines, varicella-zoster
Read more Press Releases from Rania Hafez:- Allergan and CMO at Altheos to speak at Ocular Drug Discovery conference Feb 27-28, 2012 Las Vegas
- AstraZeneca, GSK to speak at Anti-infectives Partnering meeting Nov 7-8, Boston
- Glenn D. Prestwich to speak at 7th Modern Drug Discovery Summit Oct 19-21 2011 in San Diego, CA
- Vice President at Johnson and Johnson to speak at Modern Drug Summit Oct 19-21 2011 in San Diego, CA
- Biosimilars and FDA talk at 4th Protein Discovery & Therapeutics Conference Oct 19-21 in San Diego
- Dr. Joseph Joyce, Director At Merck & Co., To Speak At Vaccines Meeting On Nov. 7-8 In Boston, MA.
- Klarquist Sparkman to speak at 4th Protein Discovery & Therapeutics Meeting Oct 19-21 in San Diego
- Dr. Philip Dormitzer, Head at Novartis, to Speak at Vaccines Meeting on Nov. 7-8 in Boston, MA
- Klaus Mendla, Global Head at Boehringer to speak at CNS Partnering meeting Sept 22-23, San Francisco
- Dr. Kanta Subbarao, Chief at the NIH, to speak at vaccines meeting on Nov. 7-8 in Boston, MA
Other Press Release Headlines:
